Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

Withdrawn applications Remove Withdrawn applications filter Referrals Remove Referrals filter Shortages Remove Shortages filter European public assessment reports (EPAR) (128) Apply European public assessment reports (EPAR) filter Summaries of opinion (8) Apply Summaries of opinion filter Paediatric investigation plans (70) Apply Paediatric investigation plans filter Orphan designations (70) Apply Orphan designations filter Direct healthcare professional communication (18) Apply Direct healthcare professional communication filter

Product number

Withdrawal type

Initial authorisation (2) Apply Initial authorisation filter Post-authorisation (2) Apply Post-authorisation filter

Withdrawal date

From:

To:

Referral name

Referral status

European Commission final decision (4) Apply European Commission final decision filter Under evaluation (1) Apply Under evaluation filter

Referral safety status

Yes (1) Apply Yes filter

Referral type

Article 20 procedures (4) Apply Article 20 procedures filter Article 31 referrals (1) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (2) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (1) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (4) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (3) Apply Risk minimisation measures filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Date of opinion

From:

To:

Decision date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Conditional approval Remove Conditional approval filter Exceptional circumstances Remove Exceptional circumstances filter Additional monitoring (24) Apply Additional monitoring filter Biosimilar (2) Apply Biosimilar filter Generic (28) Apply Generic filter Orphan medicine (44) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

9 results

Remove all filtersRemove all filters

Medicine Shortages Remove Shortages filter Withdrawn applications Remove Withdrawn applications filter Referrals Remove Referrals filter

Medicine type Conditional approval Remove Conditional approval filter Accelerated assessment Remove Accelerated assessment filter Exceptional circumstances Remove Exceptional circumstances filter

Categories Human Remove Human filter

Sort by

List item

Withdrawn application: Translarna

ataluren, date of withdrawal: 06/03/2017, Post-authorisation, Last updated: 24/03/2017
List item

Withdrawn application: Omontys

date of withdrawal: 28/06/2013, Initial authorisation, Last updated: 28/06/2013
List item

Withdrawn application: Memantine FGK

memantine, date of withdrawal: 18/12/2012, Initial authorisation, Last updated: 10/04/2013
List item

Withdrawn application: Evoltra

clofarabine, date of withdrawal: 18/03/2008, Post-authorisation, Last updated: 19/03/2008
List item

Referral: Rubraca (updated)

rucaparib, associated names: Rubraca, Article 20 procedures
Status: Under evaluation, Last updated: 24/06/2022
List item

Referral: Zynteglo

betibeglogene autotemcel, associated names: Zynteglo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 22/07/2021, EC decision date: 16/09/2021, Last updated: 11/10/2021
List item

Referral: Lartruvo

olaratumab, associated names: Lartruvo, Article 20 procedures
Status: European Commission final decision, opinion/position date: 31/01/2019, EC decision date: 19/07/2019, Last updated: 22/08/2019
List item

Referral: Factor VIII

associated names: Iblias, Elocta, Kovaltry, Nuwiq, Obizur, NovoEight, Voncento, ReFacto AF, Kogenate Bayer, Helixate NexGen, Advate, Article 31 referrals
Status: European Commission final decision, opinion/position date: 14/09/2017, EC decision date: 10/10/2017, Last updated: 05/12/2017
List item

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)

daclatasvir, dasabuvir, sofosbuvir, ledipasvir, simeprevir, ombitasvir, paritaprevir, ritonavir, associated names: Sovaldi, Olysio, Viekirax, Harvoni, Exviera, Daklinza, Article 20 procedures
Status: European Commission final decision, opinion/position date: 15/12/2016, EC decision date: 23/02/2017, Last updated: 09/03/2017

9 results

Withdrawn application: Translarna

Withdrawn application: Omontys

Withdrawn application: Memantine FGK

Withdrawn application: Evoltra

Referral: Rubraca (updated)

Referral: Zynteglo

Referral: Lartruvo

Referral: Factor VIII

Referral: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)